IP Library › Granted Patent US 12,234,254
Granted Patent B2
US 12,234,254 · App. 17/603,759 · Granted Feb 25, 2025

Methods for producing crystalline L-glufosinate ammonium monohydrate

Inventors: Brian Michael Green (Lutherville, MD); Rachel Melissa Witek (New Market, MD); Nadejda Pavlova (Gaithersburg, MD); Matthew Richard Oberholzer (Wilmington, DE)
Assignee: BASF SE
C07F9/301C12N9/0024C12Y104/03003C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,234,254
App. No.
17/603,759
Granted
Feb 25, 2025
Kind
B2
Abstract

Methods for preparing crystalline L-glufosinate ammonium monohydrate are disclosed. The methods include forming a mixture comprising water, a water-miscible organic solvent, ammonium hydroxide, and a glufosinate starting material containing L-glufosinate ammonium and D-glufosinate ammonium. L-Glufosinate ammonium monohydrate is crystallized and separated from the mixture, providing L-glufosinate ammonium monohydrate Form B. Compositions and methods employing the crystalline L-glufosinate ammonium monohydrate are also described.

Claims (42)

1. A method for preparing crystalline L-glufosinate ammonium monohydrate, the method comprising:

(i) forming a mixture comprising a L-glufosinate starting material and an aqueous solution,

wherein the glufosinate starting material comprises L-glufosinate ammonium and D-glufosinate ammonium, and

wherein the aqueous solution comprises water and a water-miscible organic solvent;

(ii) crystallizing L-glufosinate ammonium from the mixture of step (i) to form L-glufosinate ammonium monohydrate crystals; and

(iii) separating at least a portion of the L-glufosinate ammonium monohydrate crystals from the aqueous solution following step (ii);

thereby preparing the crystalline L-glufosinate ammonium monohydrate,

wherein the crystalline L-glufosinate ammonium monohydrate comprises L-glufosinate ammonium monohydrate Form B.

2. The method of claim 1 , wherein the aqueous solution further comprises of an ammonia source.

3. The method of claim 2 , wherein the ammonia source is ammonium hydroxide.

4. The method of claim 1 , wherein the molar ratio of the L-glufosinate ammonium to the D-glufosinate ammonium in the glufosinate starting material is at least 70:30.

5. The method of claim 1 , wherein the molar ratio of the L-glufosinate ammonium to the D-glufosinate ammonium in the L-glufosinate starting material is at least 76:24.

6. The method of claim 1 , wherein the L-glufosinate starting material further comprises one or more components selected from the group consisting of L-glutamate and salts thereof, D-glutamate and salts thereof, L-pyroglutamate and salts thereof, 2-oxoglutarate and salts thereof, succinic acid and salts thereof, 2-oxo-4-(hydroxy(methyl)phosphinoyl)butyric acid and salts thereof, sodium sulfate, ammonium sulfate, sodium chloride, ammonium chloride, monosodium phosphate, disodium phosphate, monoammonium phosphate, and diammonium phosphate.

7. The method of claim 6 , wherein the L-glufosinate starting material comprises L-glutamate.

8. The method of claim 1 , wherein the amount of glufosinate in the L-glufosinate starting material ranges from about 70% (w/w) to about 90% (w/w).

9. The method of claim 8 , wherein the amount of glufosinate in the L-glufosinate starting material ranges from about 75% (w/w) to about 85% (w/w).

10. The method of claim 1 , wherein the water-miscible solvent is selected from the group consisting of methanol, ethanol, 1-propanol, 2-propanol, acetonitrile, tetrahydrofuran, 1,4-dioxane, 1-methyl-2-propanol, 1,2-propanediol, and 1,2-ethanediol.

11. The method of claim 10 , wherein the water-miscible organic solvent is methanol.

12. The method of claim 1 , wherein the ratio of the water-miscible organic solvent to the water in the aqueous solution ranges from about 45:55 to about 95:5 by volume.

13. The method of claim 1 , wherein the ratio of the water-miscible organic solvent to the water in the aqueous solution ranges from about 45:55 to about 65:35 by volume.

14. The method of claim 1 , wherein the concentration of ammonium hydroxide in the aqueous solution ranges from about 0.1M to about 1M.

15. The method of claim 14 , wherein the concentration of ammonium hydroxide in the aqueous solution is about 0.4 M.

16. The method of claim 1 , wherein the ratio of the L-glufosinate starting material to the aqueous solution in step (i) ranges from about 0.5:1 to about 5:1 by weight.

17. The method of claim 16 , wherein the ratio of the L-glufosinate starting material to the aqueous solution in step (i) ranges from about 1:1 to about 2:1 by weight.

18. The method of claim 1 , wherein step (ii) comprises heating the mixture of step (i) to form a heated mixture.

19. The method of claim 18 , wherein the mixture of step (i) is heated to at least around 45° C.

20. The method of claim 17 , wherein the heated mixture is maintained at a temperature of at least around 45° C. for a period of time ranging from about 10 minutes to about 6 hours prior to step (iii).

21. The method of claim 18 , further comprising cooling the heated mixture to form a cooled mixture prior to step (iii).

22. The method of claim 21 , wherein the heated mixture is cooled to a temperature around 30° C. or less.

23. The method of claim 1 , wherein step (ii) comprises adding glufosinate seed crystals to the mixture of step (i).

24. The method of claim 18 , comprising adding glufosinate seed crystals to the heated mixture of step (ii).

25. The method of claim 23 , wherein the glufosinate seed crystals comprise L-glufosinate ammonium monohydrate Form B.

26. The method of claim 23 , wherein the mixture comprising the glufosinate seed crystals is maintained at a temperature around 30° C. for a period of time ranging from about 1 hour to about 24 hours prior to step (iii).

27. The method of claim 23 , wherein the glufosinate seed crystals are added in an amount ranging from about 0.05% (w/w) to about 30% (w/w) based on the amount of glufosinate in the L-glufosinate starting material.

28. The method of claim 27 , wherein the glufosinate seed crystals are added in an amount ranging from about 0.1% (w/w) to about 0.5% (w/w) based on the amount of glufosinate in the L-glufosinate starting material.

29. The method of claim 1 , wherein separating at least a portion of the L-glufosinate crystals in step (iii) comprises filtering the mixture of step (ii), centrifuging the mixture of step (ii), or a combination thereof.

30. The method of claim 1 , further comprising one or more steps of (iv) washing the L-glufosinate ammonium monohydrate crystals; and (v) drying the L-glufosinate ammonium monohydrate crystals.

31. The method of claim 1 , wherein the crystalline L-glufosinate ammonium monohydrate further comprises D-glufosinate.

32. The method of claim 31 , wherein the molar ratio of L-glufosinate to D-glufosinate is at least 90:10.

33. The method of claim 31 , wherein the molar ratio of L-glufosinate to D-glufosinate is at least 95:5.

34. The method of claim 1 , wherein the L-glufosinate ammonium monohydrate Form B is characterized by an X-ray powder diffraction (XRPD) pattern comprises at least three peaks selected from 10.0, 11.4, 12.5, 16.5, 17.4, 18.1, 19.6, 20.0, 21.8, 22.9, 23.6, 24.0, 25.1, 25.5, 26.1, 26.3, 26.4, 27.9, 28.2, 28.4, 28.7, 29.2, 30.2, 30.9, 31.6, 31.7, 32.7, 33.0, 33.3, 34.3, 35.2, 36.7, 37.2, 37.4, 37.8, 38.3, 38.7, and 39.3°2θ, ±0.2°2θ, as determined on a diffractometer using Cu-Kα radiation.

35. The method of claim 1 , wherein the L-glufosinate ammonium monohydrate Form B is characterized by a differential scanning calorimetry (DSC) curve exhibiting an endotherm with an onset around 123° C.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2021
From: GREEN, BRIAN MICHAEL; WITEK, RACHEL MELISSA; PAVLOVA, NADEJDA; OBERHOLZER, MATTHEW RICHARD
To: AGRIMETIS, LLC
Reel/Frame 057795/0402 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2021
From: AGRIMETIS, LLC
To: BASF SE
Reel/Frame 057795/0476 →
Continuity (3)
Provisional Application 62978005 · Feb 18, 2020
Provisional Application 62834675 · Apr 16, 2019
Related Publication 20220177499A1 · Jun 9, 2022
References Cited (23)
US 4499027A · Minowa et al. · 1985 [cited by applicant]
US 4647692A · Jacewicz · 1987 [cited by applicant]
US 5420329A · Zeiss · 1995 [cited by applicant]
US 5767309A · Knorr et al. · 1998 [cited by applicant]
US 5869668A · Knorr et al. · 1999 [cited by applicant]
US 7772426B2 · Minowa et al. · 2010 [cited by applicant]
US 7795464B2 · Minowa et al. · 2010 [cited by applicant]
US 8076503B2 · Minowa et al. · 2011 [cited by applicant]
US 9834802B2 · Green et al. · 2017 [cited by applicant]
US 10260078B2 · Green et al. · 2019 [cited by applicant]
CN 106188134 · 2016 [cited by examiner]
CN 106188134A · 2016 [cited by applicant]
WO WO2018108797A1 · 2018 [cited by applicant]
WO WO2019018406 · 2019 [cited by examiner]
WO WO2019018406A1 · 2019 [cited by applicant]
WO WO2020214631A1 · 2020 [cited by applicant]
CN106188134 translated (Year: 2016). [cited by examiner]
U.S. Appl. No. 16/631,963, Nonfinal Office Action, dated May 25, 2022. [cited by applicant]
European Patent Application No. 20724290.0, Applicant's counterargument after entry into European phase, submitted with the European Patent Office on May 18, 2022. [cited by applicant]
Miller et al., Chapter 3: Solvent systems for crystallization and polymorph selection, pp. 53-109, IN: Augustijns et al. (eds.), Solvent Systems and Their Selection in Pharmaceutics and Biopharmaceutics, Springer (2007). [cited by applicant]
Bartsch et al., Stereospecific production of the herbicide phosphinothricin (glufosinate): purification of aspartate transaminase from [cited by applicant]
International Application No. PCT/US2020/028191, International Search Report and Written Opinion, mailed Jul. 9, 2020. [cited by applicant]
Pollegioni et al., New biotech applications from evolved D-amino acid oxidases, Trends Biotechnol., 29(6):276-83 (2011). [cited by applicant]